spacer
home > > autumn 2009 > monitoring progress
PUBLICATIONS


Monitoring Progress

Data monitoring committees (DMCs) are frequently used to oversee accruing data from large, pivotal double blind clinical trials where the objective is to demonstrate safety and efficacy. The various roles of the DMCs are often not fully understood or appreciated. DMCs serve two primary functions: to ensure the ethics of the clinical trial, and to provide assurance that basic objectives of the trial have a reasonable likelihood of success.

The ethical mandate is to ensure that patients are not put at undue risk by their participation in the clinical trial. Ensuring patient safety is the primary responsibility of a DMC. A DMC monitors safety outcomes as the trial is ongoing and provides a mechanism to quickly react to any untoward safety events.

The assurance objective is to use DMCs to oversee and monitor the general trial progress. These large trials represent a significant commitment of time and resources, and a DMC provides a means of monitoring essential design elements of the trial in a way that preserves credibility while providing the company with assurance that at the trial’s conclusion the basic objectives have a reasonably high likelihood of being achieved. In this capacity, the DMC can provide important feedback regarding design parameters, such as emerging trends showing lower than anticipated efficacy, unacceptable risk/benefit, or unanticipated trends in the control arm which could result in insufficient power to detect clinical efficacy.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Ron Kershner received his PhD in biostatistics from Cornell University and has worked in the areas of biostatistics and data management in the pharmaceutical industry for over 25 years. He has worked for large pharma, biotech and clinical research organisations. Currently, Ron is Vice President of Biostatistics and Data Management at AAIPharma Inc. Through his career, Ron has participated in 24 NDA submissions and has served in various capacities in over 20 DMCs. Most recently, Ron served as Chairman of a DMC, providing efficacy and safety oversight for two Phase III studies in kidney transplantation.
spacer
Ron Kershner
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

A new anti-tumour treatment is one step closer to the clinic thanks to a new collaboration between In3Bio and 3P Biopharmaceuticals

[Pamplona, November 26 2019] 3P Biopharmaceuticals, a leading Contract Development and Manufacturing Organization (CDMO) specialized in process development and cGMP manufacturing of biologics, has been chosen by In3Bio, a UK based Biotech company, to collaborate in the development of a novel anti-tumour treatment.
More info >>

White Papers

Clinical Trial Disclosure Management: Build vs. Buy

TrialScope

Because software development is our core competency, TrialScope continues to make a significant investment in our technology. We employ agile methodologies to ensure that we can maintain a continuing level of responsiveness as disclosure requirements evolve across registries and regions.
More info >>

 
Industry Events

World Vaccine Congress Europe

18-21 October 2020, Barcelona, Spain

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement